Hospital-Treated Gram-Negative Infections – Current Treatment – Current Treatment: Physician Insights – Hospital-Treated Gram-Negative Infections (US)

Most inpatients with hospital-treated gram-negative infections (GNIs) are successfully treated empirically with generic antibiotics. These agents continue to dominate the hospital-treated GNI market, thus branded products like Allergan / AbbVie’s Avycaz, Shionogi’s Fetroja, Merck & Co.’s Recarbrio, Innoviva / Entasis’s Xacduro, Tetraphase Pharmaceuticals’ Xerava, and Merck & Co.’s Zerbaxa are typically restricted to later lines of therapy. The rising antimicrobial resistance rates have created the need for safer products to effectively treat drug-resistant GNIs. In this analysis, we explore brand use in this market based on factors such as activity against key drug-resistant pathogens. Furthermore, hospital-based GNI specialists offer insight into how they treat GNIs in response to growing drug resistance.

QUESTIONS ANSWERED

• Which first-, second-, and third-line therapies are prescribed for inpatients with urinary tract infections, nosocomial pneumonia, or complicated intra-abdominal infections?
• How are physicians approaching the treatment of infections caused by drug-resistant pathogens?
• Which factors, both clinical and nonclinical, drive, and limit, the prescribing of branded agents such as Recarbrio, Fetroja, Xerava, and Xacduro?
• What will drive use of relatively new therapies, and in which infection types will they be used? Which current agents will be most affected?

PRODUCT DESCRIPTION

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.

CONTENT HIGHLIGHTS

Publication date: June 2025

Geography: United States

Primary research: Survey of 100 U.S. hospital-based, infectious disease and critical care specialists

Key drugs covered: Avycaz, Fetroja, Recarbrio, Xacduro, Xerava, Zerbaxa

Key analyses: Factors influencing disease management and treatment decisions; drivers and constraints of treatment selection; physician-reported treatment practices and brand-level patient shares; physician-reported antibiotic use by indication; physician-reported recent / anticipated changes in brand usage or treatment approach